skip to Main Content
Tilray Receives License to Produce Medical Cannabis in the European Union

PRESS RELEASE

Company Announces €20 Million Investment to Build EU Campus and Begin Operations this Year

  • Located in the BIOCANT Research Park in Cantanhede, Portugal, Tilray’s EU Campus will cultivate, process, package, and distribute GMP-grade medical cannabis products to qualified patients, pharmacies, and researchers throughout the European common market.
  • Phased build-out of the EU Campus will begin this month – including 25,000 m2 of greenhouse and 3,000 m2 of processing facilities.
  • Phase one of the build-out will increase Tilray’s annual global production capacity to 62 metric tonnes by the end of 2018.
  • €20 million capital investment, creation of 100 jobs, and research partnerships will positively impact local community.

CANTANHEDE, Portugal–(BUSINESS WIRE)–Tilray, a global pioneer in medical cannabis research and production, announced plans today to invest up to €20 million in a European Union Campus (EU Campus) after receiving licenses from the Government of Portugal to import cannabis genetics and to cultivate cannabis for medical purposes.

“Tilray’s EU Campus is another strategic milestone as we aim to build the world’s most trusted and admired medical cannabis brand,” said Brendan Kennedy, Chief Executive Officer of Tilray. “For the past two years we’ve been working hard to find the right location for cultivation, processing, and research facilities to serve rapidly growing demand for high-quality medical cannabis products in Europe. Portugal has the ideal climate to cultivate cannabis, a highly-skilled health care workforce, and a vibrant research community. It’s more environmentally-friendly and cost-effective to supply European patients from Portugal than from northern climates.”

State-of-the-Art EU Campus Will Begin Operations This Year

To establish the EU Campus, Tilray will invest up to €20 million through its affiliate, Tilray Portugal Unipessoal Lda., in multiple facilities located in and around the BIOCANT Research Park in Cantanhede, Portugal. The EU Campus will include indoor, outdoor, and greenhouse cultivation sites, as well as facilities to process, package, and distribute medical cannabis and cannabinoid-derived medical products. As a part of the BIOCANT biotechnology and life sciences research park, the EU Campus will serve as a hub supporting Tilray’s clinical research and product development efforts across Europe.

Tilray is currently leasing laboratory and indoor cultivation space within BIOCANT. This month, Tilray will begin construction on a greenhouse and a processing facility on property purchased by the company. Phase one of the project, which is expected to be complete by spring of 2018, includes an indoor laboratory and genetics bank, outdoor cultivation sites, a 10,000 m2 greenhouse, and a 1,500 m2 processing facility. Subsequent phases, which are expected to be completed by 2020, will add 15,000 m2 of greenhouse cultivation space and another 1,500 m2 for processing. Over the next three years, the project is expected to create 100 direct jobs, including highly-skilled positions.

EU Campus Accelerates Tilray’s Global Expansion Strategy

In response to considerable unmet need for high-quality medical cannabis, Tilray is investing aggressively to expand its operations around the world. In addition to Tilray Portugal Unipessoal Lda., Tilray has wholly-owned subsidiaries in Germany (Tilray Deutschland GmbH), Canada (Tilray Canada Ltd.), and Australia and New Zealand (Tilray Australia and New Zealand Pty. Ltd.).

Tilray has a proven track record as a global pioneer in the medical cannabis industry:

  • In 2014, Tilray was one of the first companies to be federally-licensed to cultivate, process and distribute medical cannabis in Canada.
  • In December 2016, Tilray became the first medical cannabis licensed producer in North America to be GMP-certified in accordance with the European Medicines Agency’s (EMA) Good Manufacturing Practice (GMP) standards. GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes. In countries new to medical cannabis, GMP certification provides regulators and health care providers with certainty that Tilray products are a safe and smart choice.
  • In 2016 and 2017, Tilray launched clinical research partnerships with world-leading hospitals and universities to study the safety and efficacy of medical cannabis for a diverse range of conditions, including post-traumatic stress disorder (PTSD), chronic obstructive pulmonary disorder (COPD), pediatric epilepsy, and chemotherapy-induced nausea and vomiting (CINV).
  • Throughout the last year, Tilray became the first company to legally export medical cannabis products from North America to the European Union, Australia, New Zealand, and South America. Tilray products are currently available in six countries spanning four continents.

By the end of 2017, Tilray expects to export medical cannabis products to five more countries. The company also anticipates announcing federal licenses from additional countries, as well as research partnerships in Portugal, Germany, and other countries around the world.

Tilray Portugal Timeline

Tilray executives first visited Portugal in 2015. After conducting extensive due diligence, consultation with stakeholders, and a country-wide property search, Tilray reached a Memorandum of Understanding with the Government of Portugal in October 2016. Tilray Portugal Unipessoal Lda. was incorporated in March 2017. The company purchased property in Cantanhede in July 2017.

About Tilray

Tilray is a global pioneer in the research and production of medical cannabis and cannabinoids. Tilray currently serves tens of thousands of patients, physicians, pharmacies, governments, hospitals, and researchers in six countries spanning four continents through its affiliated entities in Australia and New Zealand (Tilray Australia New Zealand Pty Ltd), Canada (Tilray Canada Ltd), Germany (Tilray Deutschland GmbH), and Portugal (Tilray Portugal Unipessoal Lda).

Contacts

Tilray
Portugal:
[email protected]
or
Europe:
[email protected]
or
Canada:
Chrissy Roebuck, 1-416-560-5712
[email protected]
or
Global:
Zack Hutson, +1-415-534-5541
[email protected]

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council have been identified following a special general meeting attended by around 50 members. The meeting in Arlington St, next to the Ritz Hotel, London, saw members consider part-funding a university-based cost benefit analysis into the efficacy of the medical cannabis. A second proposed work stream aims…

Does Medical Licensing Make Sense in Recreational Jurisdictions?

By Griffen Thorne, Attorney at Harris Bricken Cannabis licensing has a pretty standard trajectory by this point in time. States tend to start out with medical programs and later adopt recreational programs. What usually happens is that the recreational cannabis market swallows up the medical market. The majority of medical operators will seek out and…

Marijuana in the workplace: New York employers can’t test most workers, state says

The New York State Department of Labor has released new guidance regarding legalized recreational marijuana use and the workplace. According to that new guidance, employers must cite “articulable symptoms of impairment” in almost any effort to take action against an employee due to marijuana use. That means an employer must provide “objectively observable” evidence that…

Vermont Gears Up for a $225 Million Marijuana Market

Vermont’s Cannabis Control Board estimates that spending on recreational marijuana in Vermont could reach $225 million annually by 2025, which would translate to nearly $46 million in new state taxes. The figures are just some of the news from a highly anticipated report the board released last Friday. The 64-page document lays the groundwork for…

More Categories

Back To Top
×Close search
Search